文献速递慢性肾脏病肾血管病与高血压

强化降压期间肾功能急性下降与未来ESRD风险的关系

Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk.
PubMed 文献 · J Am Soc Nephrol · 2017-05-04

本研究回顾性分析AASK试验899例和MDRD试验761例既往随机接受严格或常规血压控制的CKD患者,评估随机分组后3-4个月(达到血压目标时间)内eGFR下降百分比与ESRD风险的关联。结果显示,强化降压组中5%至<20%的eGFR下降未与ESRD风险升高相关,但常规降压组中同等程度下降与ESRD风险升高相关;≥20%的eGFR下降在两组均与ESRD风险升高相关。

要点

  • 强化降压期间eGFR下降5%至<20%不增加ESRD风险。
  • 常规降压期间eGFR下降5%至<20%与ESRD风险升高相关。
  • eGFR下降≥20%在强化和常规降压中均提示ESRD风险升高。

核心结论

  • 强化降压期间eGFR下降5%至<20%未与ESRD风险升高相关,但≥20%的下降在强化和常规降压中均与ESRD风险升高相关。

研究设计与样本

  • 回顾性研究纳入AASK试验899例和MDRD试验761例既往随机接受严格或常规血压控制的CKD患者。

主要发现

  • 强化降压组eGFR下降5%至<20%与ESRD风险无关:AASK的aHR为1.19(95%CI 0.84-1.68),MDRD试验的aHR为1.08(95%CI 0.84-1.40)。
  • 常规降压组eGFR下降5%至<20%与ESRD风险升高相关:AASK的aHR为1.83(95%CI 1.30-2.57),MDRD试验的aHR为1.62(95%CI 1.25-2.11)。
  • eGFR下降≥20%在严格和常规降压组均与ESRD风险升高相关。

关键数值与推荐

  • eGFR下降百分比分组:<5%、5%至<20%、≥20%,基于随机分组至试验第3-4个月(达到血压目标时间)的eGFR变化。
  • 强化降压组eGFR下降5%至<20% vs <5%:AASK的aHR 1.19(95%CI 0.84-1.68),MDRD的aHR 1.08(95%CI 0.84-1.40)。
  • 常规降压组eGFR下降5%至<20% vs <5%:AASK的aHR 1.83(95%CI 1.30-2.57),MDRD的aHR 1.62(95%CI 1.25-2.11)。

临床怎么用

  • 强化降压期间eGFR下降5%至<20%可能可接受,不提示ESRD风险升高。
  • 强化降压期间eGFR下降≥20%应警惕未来ESRD风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The magnitude of decline in renal function that should be tolerated during intensive BP lowering and its association with risk of ESRD are unclear. To determine whether the acute declines in kidney function in the intensive BP lowering arm of two trials in CKD associated with higher risk of ESRD, we performed a retrospective study of 899 African American Study of Kidney Disease and Hypertension (AASK) and 761 Modification of Diet in Renal Disease (MDRD) Trial participants previously randomized to strict versus usual BP control. The predictor was the percentage decline in eGFR (<5%, 5% to <20%, or ≥20%) between randomization and months 3 and 4 of the trial (time to achieve BP goals). ESRD was the outcome of interest. Compared with a <5% eGFR decline in the usual BP arm, a 5% to <20% eGFR decline during intensive BP lowering did not associate with a higher risk of ESRD in the AASK (adjusted hazard ratio [aHR], 1.19; 95% confidence interval [95% CI], 0.84 to 1.68) or the MDRD Trial (aHR, 1.08; 95% CI, 0.84 to 1.40). However, a 5% to <20% eGFR decline in the usual BP arm associated with higher risk of ESRD in AASK (aHR, 1.83; 95% CI, 1.30 to 2.57) and MDRD Trial (aHR, 1.62; 95% CI, 1.25 to 2.11). A ≥20% eGFR decline associated with higher risk of ESRD in both strict and usual BP arms. Thus, acute eGFR declines ≥20% during intensive BP lowering identified a subset of patients at higher risk for adverse outcomes.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Ku E, Bakris G, Johansen KL, et al. Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017. PMID: 28473636. doi:10.1681/ASN.2017010040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。